Health Condition 1: E00-E89- Endocrine, nutritional and metabolic diseases
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1.Adult hypogonadal men =18 who are already on stable dose of Intramuscular Testosterone Enanthate therapy for more than 3 months duration
Exclusion criteria
Exclusion criteria: 1.Coexistent Liver /Renal dysfunction 2.Congestive heart failure 3.History of following within the last 6 months of screening: Myocardial infarction (MI), unstable angina leading to hospitalization, percutaneous coronary intervention, coronary artery bypass graft, uncontrolled cardiac arrhythmia, stroke transient ischemia attack, carotid revascularization, endovascular procedure, or surgical intervention for peripheral vascular disease 4.Systemic infections 5.Positive serology for HIV, hepatitis B or hepatitis C 6.Skin conditions in injection site that could confound injection site assessments. 7.Use of other androgens (DHEA), anabolic steroids, other sex hormones) or other substances/supplements 8.History or current evidence of breast or prostate cancer 9.Elevated prostate-specific antigen (PSA) for age 10.H/o psychiatric illnesses
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To study the effects of subcutaneous injection Testosterone enanthate on Peak and trough Serum Testosterone concentrations when compared to Intramuscular administration of Injection Testosterone enanthate.Timepoint: at end of 4 weeks of Intramusular injection. On day 1,3 and 7 of every week following subutanous injection in month 1 , and month 3 | — |
Secondary
| Measure | Time frame |
|---|---|
| To compare the effects of Subcutaneous Testosterone Injection enanthate with Intramuscular Testosterone enanthate in terms of 1. Quality of life 2. Adverse Drug Reactions Timepoint: over 1 year | — |
Countries
India
Contacts
Topiwala National Medical college